Clínic Barcelona

Belimumab is the first treatment specifically developed for SLE in over 50 years

GlaxoSmithKline (GSK) and Human Genome Sciences (HGS) presented BENLYSTA (belimumab). This is a treatment for adult patients with systemic lupus erythematosus (SLE) who have a high degree of disease activity and in which the disease is not controlled despite receiving therapies. This drug is a treatment specifically indicated for reducing disease activity in SLE. Dr. Ricard Cervera, head of Department of Autoimmune Diseases at IDIBAPS - Hospital Clínic of Barcelona and one of the principal investigators of this drug, has participated in the presentation.